Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons

Experimental Gerontology

Volumn 42, Issue 3, 2007, Pages 215-222

  Attems, Johannes ^a   Quass, Magdalena ^a   Gartner, Wolfgang ^b   Nabokikh, Anastasiya ^b   Wagner, Ludwig ^b   Steurer, Stefan ^a   Arbes, Stefanie ^a   Lintner, Felix ^a   Jellinger, Kurt ^c  

^a OTTO WAGNER HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Alzheimer disease; Calcium binding protein; Calcium sensor protein; Human hippocampus; Secretagogin

Indexed keywords

CALCIUM BINDING PROTEIN; PROTEIN ANTIBODY; SECRETAGOGIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INCUBATION TIME; MALE; NERVE CELL; NEUROPATHOLOGY; NEUROPIL; PRIORITY JOURNAL; PROBABILITY; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION; STAINING; STATISTICAL SIGNIFICANCE; SUBICULUM;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOTTING, WESTERN; CADAVER; CALCIUM-BINDING PROTEINS; DENTATE GYRUS; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROPIL; PYRAMIDAL CELLS;

EID: 33846227970     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2006.09.018     Document Type: Article

References (49)

1. Abu-Soud H.M., and Stuehr D.J. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci USA 90 (1993) 10769-10772
2. Arai H., Emson P.C., Mountjoy C.Q., Carassco L.H., and Heizmann C.W. Loss of parvalbumin-immunoreactive neurones from cortex in Alzheimer-type dementia. Brain Res 418 (1987) 164-169
3. Bernstein H.G., Blazejczyk M., Rudka T., Gundelfinger E.D., Dobrowolny H., Bogerts B., Kreutz M.R., Kuznicki J., and Wojda U. The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains. Neuropathol Appl Neurobiol 31 (2005) 314-324
4. Birkenkamp-Demtroder K., Wagner L., Brandt Sorensen F., Bording Astrup L., Gartner W., Scherubl H., Heine B., Christiansen P., and Orntoft T.F. Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology 82 (2005) 121-138
5. Blandini F., Braunewell K.H., Manahan-Vaughan D., Orzi F., and Sarti P. Neurodegeneration and energy metabolism: from chemistry to clinics. Cell Death Differ 11 (2004) 479-484
6. Braak E., Strotkamp B., and Braak H. Parvalbumin-immunoreactive structures in the hippocampus of the human adult. Cell Tissue Res 264 (1991) 33-48
7. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
8. Brady D.R., and Mufson E.J. Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Neuroscience 80 (1997) 1113-1125
9. Braunewell K.H., and Gundelfinger E.D. Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell Tissue Res 295 (1999) 1-12
10. Brion J.P., and Resibois A. A subset of calretinin-positive neurons are abnormal in Alzheimer's disease. Acta Neuropathol (Berl) 88 (1994) 33-43
11. 2+-binding proteins. Biochem J 353 (2001) 1-12
12. Dalgarno D., Klevit R.E., Levine B.A., and Williams R.J.P. The calcium receptor and trigger. Trends Pharmacol Sci 4 (1984) 266-271
13. DeFelipe J. Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex. J Chem Neuroanat 14 (1997) 1-19
14. del Rio M.R., and DeFelipe J. Synaptic connections of calretinin-immunoreactive neurons in the human neocortex. J Neurosci 17 (1997) 5143-5154
15. Drewes G., Mandelkow E.M., Baumann K., Goris J., Merlevede W., and Mandelkow E. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett 336 (1993) 425-432
16. Ferrer I., Soriano E., Tunon T., Fonseca M., and Guionnet N. Parvalbumin immunoreactive neurons in normal human temporal neocortex and in patients with Alzheimer's disease. J Neurol Sci 106 (1991) 135-141
17. Fonseca M., Soriano E., Ferrer I., Martinez A., and Tunon T. Chandelier cell axons identified by parvalbumin-immunoreactivity in the normal human temporal cortex and in Alzheimer's disease. Neuroscience 55 (1993) 1107-1116
18. Gandhi C.R., and Keenan R.W. The role of calmodulin in the regulation of dolichol kinase. J Biol Chem 258 (1983) 7639-7643
19. Gartner W., Lang W., Leutmetzer F., Domanovits H., Waldhausl W., and Wagner L. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex 11 (2001) 1161-1169
20. Geula C., Nagykery N., Wu C.K., and Bu J. Loss of calbindin-D28K from aging human cholinergic basal forebrain: relation to plaques and tangles. J Neuropathol Exp Neurol 62 (2003) 605-616
21. Greene J.R., Radenahmad N., Wilcock G.K., Neal J.W., and Pearson R.C. Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease. Neuropathol Appl Neurobiol 27 (2001) 339-342
22. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
23. Hof P.R., Cox K., Young W.G., Celio M.R., Rogers J., and Morrison J.H. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer's disease. J Neuropathol Exp Neurol 50 (1991) 451-462
24. Hof P.R., Glezer II, Conde F., Flagg R.A., Rubin M.B., Nimchinsky E.A., and Vogt Weisenhorn D.M. Cellular distribution of the calcium-binding proteins parvalbumin, calbindin, and calretinin in the neocortex of mammals: phylogenetic and developmental patterns. J Chem Neuroanat 16 (1999) 77-116
25. Hof P.R., Nimchinsky E.A., Celio M.R., Bouras C., and Morrison J.H. Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer's disease. Neurosci Lett 152 (1993) 145-148
26. Hof P.R., Rosenthal R.E., and Fiskum G. Distribution of neurofilament protein and calcium-binding proteins parvalbumin, calbindin, and calretinin in the canine hippocampus. J Chem Neuroanat 11 (1996) 1-12
27. Holscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5 (1998) 129-141
28. Hyman B.T. New neuropathological criteria for Alzheimer disease. Arch Neurol 55 (1998) 1174-1176
29. Iacopino A.M., and Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87 (1990) 4078-4082
30. Ikura M. Calcium binding and conformational response in EF-hand proteins. Trends Biochem Sci 21 (1996) 14-17
31. Inaguma Y., Shinohara H., Inagaki T., and Kato K. Immunoreactive parvalbumin concentrations in parahippocampal gyrus decrease in patients with Alzheimer's disease. J Neurol Sci 110 (1992) 57-61
32. Leifer D., and Kowall N.W. Immunohistochemical patterns of selective cellular vulnerability in human cerebral ischemia. J Neurol Sci 119 (1993) 217-228
33. Leuba G., Kraftsik R., and Saini K. Quantitative distribution of parvalbumin, calretinin, and calbindin D-28k immunoreactive neurons in the visual cortex of normal and Alzheimer cases. Exp Neurol 152 (1998) 278-291
34. Mattson M.P., and Chan S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J Mol Neurosci 17 (2001) 205-224
35. Mikkonen M., Alafuzoff I., Tapiola T., Soininen H., and Miettinen R. Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer's disease. Neuroscience 92 (1999) 515-532
36. Mirra S.S., Hart M.N., and Terry R.D. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 117 (1993) 132-144
37. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., and Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
38. Nitsch C., Scotti A., Sommacal A., and Kalt G. GABAergic hippocampal neurons resistant to ischemia-induced neuronal death contain the Ca2(+)-binding protein parvalbumin. Neurosci Lett 105 (1989) 263-268
39. Nitsch R., and Ohm T.G. Calretinin immunoreactive structures in the human hippocampal formation. J Comp Neurol 360 (1995) 475-487
40. Rogstam A., Linse S., Lindqvist A., James P., Wagner L., and Berggard T. Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochem J (2006)
41. Satoh J., Tabira T., Sano M., Nakayama H., and Tateishi J. Parvalbumin-immunoreactive neurons in the human central nervous system are decreased in Alzheimer's disease. Acta Neuropathol (Berl) 81 (1991) 388-395
42. Scharfman H.E., and Schwartzkroin P.A. Protection of dentate hilar cells from prolonged stimulation by intracellular calcium chelation. Science 246 (1989) 257-260
43. Seress L., Gulyas A.I., Ferrer I., Tunon T., Soriano E., and Freund T.F. Distribution, morphological features, and synaptic connections of parvalbumin- and calbindin D28k-immunoreactive neurons in the human hippocampal formation. J Comp Neurol 337 (1993) 208-230
44. Skelton N.J., Kordel J., Akke M., Forsen S., and Chazin W.J. Signal transduction versus buffering activity in Ca(2+)-binding proteins. Nat Struct Biol 1 (1994) 239-245
45. Solomon B., Koppel R., and Jossiphov J. Immunostaining of calmodulin and aluminium in Alzheimer's disease-affected brains. Brain Res Bull 55 (2001) 253-256
46. Thibault O., Porter N.M., Chen K.C., Blalock E.M., Kaminker P.G., Clodfelter G.V., Brewer L.D., and Landfield P.W. Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Cell Calcium 24 (1998) 417-433
47. 2+-binding protein. J Biol Chem 275 (2000) 24740-24751
48. Zhan X., Evans C.O., Oyesiku N.M., and Desiderio D.M. Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary 6 (2003) 189-202
49. Zierhut B., Daneva T., Gartner W., Brunnmaier B., Mineva I., Berggard T., and Wagner L. Setagin and secretagogin-R22: Posttranscriptional modification products of the secretagogin gene. Biochem Biophys Res Commun 329 (2005) 1193-1199